$2.23 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Geron

Geron Corporation (Geron) is a late-stage clinical biopharmaceutical company, which is focused on development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat includes IMerge, a Phase II/III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis.

Stock Analysis

last close $2.19
1-mo return 26.6%
3-mo return 68.5%
avg daily vol. 3.88M
52-week high 2.67
52-week low 0.99
market cap. $888M
forward pe -
annual div. -
roe -73.5%
ltg forecast -
dividend yield -
annual rev. $1M
inst own. 52.4%

Subscribe now for daily local and international financial news